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Abstract
NG2/CSPG4 is a complex surface-associated proteoglycan (PG) recognized to be a widely expressed membrane
component of glioblastoma (WHO grade IV) cells and angiogenic pericytes. To determine the precise expression
pattern of NG2/CSPG4 on glioblastoma cells and pericytes, we generated a panel of >60 mouse monoclonal
antibodies (mAbs) directed against the ectodomain of human NG2/CSPG4, partially characterized the mAbs, and
performed a high-resolution distributional mapping of the PG in human foetal, adult and glioblastoma-affected brains.
The reactivity pattern initially observed on reference tumour cell lines indicated that the mAbs recognized 48
immunologically distinct NG2/CSPG4 isoforms, and a total of 14 mAbs was found to identify NG2/CSPG4 isoforms in
foetal and neoplastic cerebral sections. These were consistently absent in the adult brain, but exhibited a
complementary expression pattern in angiogenic vessels of both tumour and foetal tissues. Considering the extreme
pleomorphism of tumour areas, and with the aim of subsequently analysing the distributional pattern of the NG2/
CSPG4 isoforms on similar histological vessel typologies, a preliminary study was carried out with endothelial cell
and pericyte markers, and with selected vascular basement membrane (VBM) components. On both tumour areas
characterized by 'glomeruloid' and 'garland vessels', which showed a remarkably similar cellular and molecular
organization, and on developing brain vessels, spatially separated, phenotypically diversified pericyte subsets with a
polarized expression of key surface components, including NG2/CSPG4, were disclosed. Interestingly, the majority of
the immunolocalized NG2/CSPG4 isoforms present in glioblastoma tissue were present in foetal brain, except for one
isoform that seemed to be exclusive of tumour cells, being absent in foetal brain. The results highlight an
unprecedented, complex pattern of NG2/CSPG4 isoform expression in foetal and neoplastic CNS, discriminating
between phenotype-specific and neoplastic versus non-neoplastic variants of the PG, thus opening up vistas for
more selective immunotherapeutic targeting of brain tumours.
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Introduction
The most frequent and malignant type of brain tumour, high
grade-glioblastoma (WHO grade IV), is an infiltrating and highly
vascularized neoplasia that is highly resistant to chemotherapy
and radiotherapy and is therefore associated with poor
prognosis [1-3]. Neovascularization plays a pivotal role in the
propagation and therapeutic refraction of glioblastoma and,
accordingly, vessel density is correlated with malignancy and
routinely employed as a prognostic indicator [4,5]. Neovessels
and their patterning within glioblastoma lesions are
morphologically peculiar [6-9], and four principal features of this
angiogenic pattern can be distinguished: (1) a high density of
vessels at the border of the brain parenchyma suggesting the
occurrence of an active sprouting process at the invasive front
of the lesion; (2) a similarly active intralesional sprouting
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generating an enrichment of neovessels within the tumour
mass; (3) an endothelial hyperplasia defining garland vessels
(a diagnostic criterion for grade IV glioblastoma); and (4) the
presence of glomeruloid structures characterized by actively
proliferating endothelial cells and pericytes [10].
Numerous prognostic markers have been proposed for
gliomas and among these NG2/CSPG4 - a unique
transmembrane chondroitin sulphate proteoglycan (CSPG) –
has been suggested to be one of the foremost [11-17]. NG2/
CSPG4 is characterized by numerous glycosylation sites and
three putative glycosaminoglycan (GAG)-attachment sites,
making it prone to be expressed as multiple and intricate
glycoforms. However, the pattern of expression of such
putative isoforms, the modes through which they may be
generated, and their precise nature in healthy and neoplastic
tissues are still under investigation. In most cases, only one of
the three GAG-attachment sites is substituted by a relatively
short chondroitin sulphate chain, whereas in several instances
(especially in cancer cells) NG2/CSPG4 seems to be
intercalated into the plasma membrane as a GAG-free
molecule. In its fully glycosylated form NG2/CSPG4 has an
apparent molecular weight of >500 kDa and this isoform often
coexists with less glycosylated variants running in the range of
250-300 kDa by SDS-PAGE.
The abundance of NG2/CSPG4 in glioblastoma samples is
believed to stem from its pronounced expression on early CNS
glial progenitors and high levels on pericytes of intra-lesional
neovessels [18-25]. This specific expression pattern suggests
that NG2/CSPG4 may be an effective therapeutic target for the
treatment of cerebral tumours. In fact, siRNA-mediated
abrogation of NG2/CSPG4 in human and animal xenograft
models of glioblastoma retards tumour growth and suppresses
its invasiveness [26] and mouse antibody 9.2.27 in combined
immunotherapy with immune cells in GBM-bearing rats may
mediate anti-tumour effects [27]. Interestingly, however,
although glial precursors are highly dependent upon NG2/
CSPG4 and its PDGF-co-receptor activity, experimentally
induced gliomagenesis through forced overexpression of
PDGF is indistinguishable in wild type and NG2/CSPG4-KO
mice [28], suggesting that (at least in the mouse) NG2/CSPG4
is not involved in the inception of glioblastoma through
dysregulation of the signalling induced by this proto-oncogene.
A further point of note is that NG2/CSPG4 is normally
present on <50% of glioblastoma cells, suggesting that it is
associated with specific cell subsets of this tumour. On the
other hand, it has not yet been fully established whether NG2/
CSPG4 expression coincides with CD133-expressing and non-
expressing cancer initiating/stem cells [15,16,29], or whether it
identifies alternative, highly malignant cancer cell populations.
The possibility that glioblastoma may originate, at least in part,
from neoplastic transformation of NG2/CSPG4-expressing glial
cells is an attractive hypothesis [19,30], but not fully supported
by experimental data [29,31,32].
In light of the potential significance of NG2/CSPG4 in the
progression and treatment of glioblastoma, we have generated
a wide panel of antibodies against the PG ectodomain and
have employed these immunological tools to disclose
transitional embryonic-to-adult-to-neoplastic expression
patterns of distinct PG isoforms.
Materials and Methods
Ethics Statement
Samples of foetal brain were obtained from four post-mortem
foetuses derived from spontaneous abortions and received by
the Department of Pathological Anatomy, University of Bari
School of Medicine. Tissue preparation and storage were as
previously described [33], all samples used here were taken
post-mortem from the same foetuses. The study was approved
by the Ethics Committee of the University of Bari Medical
School and complied with the principles stated in the
Declaration of Helsinki.
Tissue samples, from glioblastoma patients and controls
from temporal lobes after selective amygdalohippocampectomy
in patients with chronic pharmaco-resistant mesial temporal
lobe epilepsy, were obtained during surgery at the Department
of Neurosurgery, University Hospital Zurich. Written informed
consent was obtained from patients before study entry. All
procedures were conducted in accordance with the Declaration
of Helsinki and the study was approved by the Ethics
Committee of the Canton Zurich.
Immunizations, blood sampling and euthanizing of animals
were performed in compliance with standard protocols
approved by the Italian Ministry of Health Committee and by
the institutional Bioethics Committee of the National Cancer
Institute Aviano, CRO-IRCCS, Aviano, Italy, emanated through
the local Animal Care and Use Committee, with the support of
the Veterinary Surveillance Unit. The protocols involved all
preventive measures to avoid animal distress and suffering.
Female Balb/c mice used for monoclonal antibody production
were kept in specified pathogen-free conditions, experiments
were performed on 4-6-weeks old females bred and housed in
the animal facility of the CRO-IRCCS.
Production of anti-NG2 antibodies
Female Balb/c mice were immunized with the recombinant
His-tagged extracellular portion of human NG2/CSPG4 (amino
acids 1-2184 of the protein inserted into a pEF6V5his vector)
produced in HEK293 cells by repeated intraperitoneal
injections of the immunogen solubilized in complete Freund’s
adjuvant (Sigma-Aldrich, St Louis, MI, USA). From ELISA
screenings of 63 hybridoma clones generated by fusion of NS1
murine myeloma cells with spleen cells from mice that
developed an anti-NG2 immune-response, we selected 48
clones for further characterization. Reactivity traits of these
clones were initially established by immunohistochemistry,
using sections from paraffin-embedded 22-week-old human
foetal brain tissues and glioblastoma sections (see below), and
by immunoblotting using the immunogen and a number of
human melanoma and soft-tissue sarcoma cell lines (see
below). A number of hybridoma clones that exhibited unique
immunostaining and immunoblotting banding patterns were
further subcloned, their Igs isotyped using the Pierce® Rapid
ELISA Mouse mAb Isotyping kit (ThermoScientifics Inc), and
Pericyte Subsets Express NG2/CSPG4 Isoforms
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used for the production of ascites fluids in Balb/c or athymic
mice.
Other antibodies
The anti-NG2 polyclonal antiserum D2 was kindly provided
by William Stallcup (The Sanford-Burnham Institute for Medical
Research, La Jolla, CA, USA). In our previous study we found
that in the foetal CNS this antiserum recognizes NG2/CSPG4
isoforms expressed by angiogenic pericytes, but does not react
with NG2/CSPG4 of oligodendrocyte precursors [34].
Hybridoma cells producing the anti-NG2 mAb B5/M28 were
obtained from ATCC (American Tissue and Cell Collection,
ATCC, Rockville, MD, USA). The PE-conjugated anti-NG2/
CSPG4 mouse mAb 7.1 was purchased from Beckman-
Coulter. The antiserum against β-actin was purchased from
Sigma-Aldrich.
Cell-ELISA
Human cell lines utilized were as follows: A375, M2 and
COLO-38, melanoma; SK-UT-1 and SK-LMS-1,
leiomyosarcoma, HT1080, fibrosarcoma; 143B, osteosarcoma;
all cell lines were from ATCC. Cells were cultured in DMEM
(Dulbecco’s modified Eagle’s medium, Life Technologies Inc),
low glucose (1.0 g/L), supplemented with Pen/Strep, L-
Glutamine and 10% FBS (Foetal Bovine Serum; Life
Technologies Inc., Carlsbad, CA, USA). For Cell-ELISA, cells
were seeded in 96 well plates at a density of 10,000 cells/well
in the above medium. Cells were washed, fixed with 2%
paraformaldehyde (PFA) for 30 min, washed and endogenous
peroxidase activity blocked by incubation with 3% H2O2 for 15
min at room temperature. For reducing non-specific Ig binding,
cells were further incubated with a blocking buffer (PBS with
2% BSA, 10% sucrose, 0.1% NaN3) for 30 min at room
temperature. Cells were then incubated overnight at 4°C with
the anti-NG2/CSPG4 mAbs, diluted in blocking buffer. The
Streptavidin/Biotin/HRP system (Thermo Scientific, TS-125-HR
and TM-125-BN) and TMB as a HRP substrate (Sigma-Aldrich)
was then employed as recommended by the manufacturer for
the detection of antibody binding. All assays were performed at
least in triplicate.
Flow cytometry
Cells were detached from the substrate and collected by
incubation in 5 mM EDTA. After extensive washing in PBS,
they were re-suspended in PBS at a concentration of 5x106
cells/ml and a volume of 50µl of this cell suspension was
incubated for 15 min at room temperature with 1µl of mouse
IgG-PE or 20µl of mAb 7.1-PE. Cells were then washed with
PBS and re-suspended in 300µl PBS for analysis. All
measurements were performed with a FACSCalibur (BD
Biosciences, Inc., San Jose, CA, USA) using 10,000 gated
events for each sample. A gate was set during acquisition on
the forward scatter versus side scatter plot to exclude possible
cell debris. The positivity for NG2/CSPG4 was determined by
examining the F2 channel at a value of 543 for HT1080 cells
used as reference cells.
Human glioblastoma, healthy and foetal brain samples
Patients underwent conventional contrast-enhanced MRI
using a 1.5T MR system (Siemens, Avanto, Philadelphia, PA,
USA) with an 8 channels head coil at baseline. Each scan was
evaluated for the tumour characteristics (lesion size at greatest
diameter in any acquisition plane, location, contrast
enhancement, perilesional oedema, and necrosis) by a
neuroradiologist of the Institute of Neuropathology, University
Hospital Zurich. Tumour localization was the bifrontal/corpus
callosum (n=3), right occipito-parietal (n=2), left parietal/corpus
callosum (n=3), left post-central/left thalamus (n=1), right
fronto-insulo-temporal (n=4), right temporal (n=3); specimens
size ranged from 2x3x2cm to 3x4x5.5 cm. Histological
diagnosis, on tumour samples from sixteen glioblastoma
patients and on parahippocampal control samples from six
patients with chronic pharmaco-resistant mesial temporal lobe
epilepsy, was performed by routine clinical neuropathology
examination at the same institution. Glioma samples were
classified according to the WHO criteria and submitted,
together with control specimens, to the same histological and
IHC procedures as described above for foetal samples.
Samples of foetal brain were collected post-mortem from four
22-week-old human foetuses that did not reveal macroscopic
structural abnormalities at autopsy and/or microscopic
malformations of the central nervous system after conventional
histological analysis with H&E or toluidine blue stainings. The
foetal age was estimated on the basis of the crown-rump length
and/or pregnancy records (counting from the last menstrual
period). The dorso-lateral wall of the telencephalic vesicles
(future neocortex) was dissected and fixed in small 0.5 cm thick
samples for 2-3 hrs at 4°C by immersion in 2% PFA plus 0.2%
glutaraldehyde in a phosphate buffered saline solution (PBS,
pH 7.6). Each sample was then washed in PBS and divided
into two equal parts, one of which was embedded in paraffin
wax and one stored at 4°C in PBS plus 0.02% PFA.
Immunohistochemistry
Samples of foetal telencephalon, control tissue, and
glioblastoma embedded in paraffin were cut into 5-µm serial
sections and collected on VectabondTM treated slides (Vector
Laboratories Inc., Burlingame, CA, USA). Sections were
rehydrated in blocking buffer-PBS (BB; 1% bovine serum
albumin, 2% FCS), treated with 1% H2O2 in 90% methanol for
20 min at room temperature to quench endogenous peroxidase
activity, washed twice in BB, incubated with one of the anti-
NG2/CSPG4 monoclonal antibodies (mAbs; 48 original
hybridoma clones and 134 subclones for a total of 182 different
primary antibodies) overnight at 4°C, and then sequentially
incubated with HRP-streptavidin (Vector Laboratories) and the
substrate-chromogen 3-amino-9-ethylcarbazole (AEC, Vector
Laboratories). Sections were finally counterstained with
haematoxylin and coverslipped with Glycergel (Dako Italia,
Milan, Italy). For negative controls the primary antibody was
omitted or pre-incubated with an excess of recombinant NG2/
CSPG4. Staining intensity was assessed blindly on a multi-
level score by two independent observers.
Through this initial screening we were able to cluster the
entire set of anti-NG2/CSPG4 antibodies into four classes
Pericyte Subsets Express NG2/CSPG4 Isoforms
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according to their staining pattern. Within each class a
prototype antibody was selected, in virtue of its staining
reproducibility and intensity, to be applied in the subsequent
analyses. Single and multiple immunolabellings were carried
out with the following polyclonal antisera (pAbs) and
monoclonal antibodies (mAbs), all diluted in BB: mAb anti-
CD31, pAb anti-CD105/endoglin, mAb anti-MMP-2, pAb anti-
Glut-1, pAb anti-NG2 D2 (generous gift from William B.
Stallcup), mAb anti-CD248/endosialin, clone B1/22.4 (generous
gift from Prof. Claire M. Isacke, The Breakthrough Breast
Cancer Research Centre, London, UK), mAb anti-phospho-
PDGFR-β (Tyr751), pAb anti- PDGFR-β, mAb anti-αSMA, pAb
anti-collagen type IV, mAb anti-collagen type IV, pAb anti-
collagen type VI, pAb anti-CD3, mAb anti-CD45, mAb anti-
CD146, mAb anti-O4 (Table S1). Tissue sections were allowed
to attach to polylysine slides (Menzel-Glaser, GmbH,
Braunschweig, Germany) by drying for 10 min at room
temperature (RT), rehydrated with PBS for 5 min at RT, and
(for anti-CD105/endoglin) processed by microwave pre-
treatment in 0.01 M citrate buffer (pH 6.0) for 15 min at 750 W.
They were then incubated with 0.5 % Triton X-100 in PBS for
30 min at RT and with BB 30 min at RT, followed by incubation
with single or combined primary antibodies overnight at 4°C
and incubation with appropriate fluorophore-conjugated
secondary antibodies or appropriate biotinylated secondary
antibodies, always diluted in BB and subsequently revealed by
fluorophore-conjugated streptavidin (Table S1). After
immunolabelling, the sections were fixed in 4 % PFA for 10
min, counterstained with TO-PRO3 diluted 1:10 K in PBS for 5
min at RT (633; Life Technologies, Inc., Gaithersburg, MD,
USA) and coverslipped with Vectashield (Vector). The stained
sections were examined under the Leica TCS SP5 confocal
laser-scanning microscope (Leica Microsystems, Mannheim,
Germany) using a sequential scanning procedure. Confocal
images were taken at 250 nm intervals through the z-axis of
the sections with 40x and 63x oil immersion lenses. z-stacks of
serial optical planes (projection images) and single optical
planes were analyzed by Leica confocal software (Multicolour
Package; Leica Microsystems). The size of immunostained
cells observed in the vessel lumen was evaluated with LASAF
SP5 software (Leica Microsystems) using a x63 oil immersion
lens. The diameter of microvesicles released by endothelial
cells (ECs) and the diameter of NG2/CSPG4-reactive pericyte
precursor cells (PPCs) was measured on single optical planes
from CD31/Coll IV and pAb NG2 D2/mAb 2161D7-labelled
sections (n=15), total vascular fields n=60 and n=23,
respectively. The results were expressed as mean ± SD.
SDS-PAGE and Western blotting
Cells were washed with ice-cold PBS and solubilized at 4°C
with RIPA lysis buffer (50mM Tris, pH 7.4; 150mM NaCl; 0.5%
Na-deoxycholate, 0.1% SDS, 1% Nonidet P-40, 2mM EDTA,
Pefabloc® SC 0.8mM, 1 tablet of “complete mini” Roche) for 15
minutes. Lysed cells were centrifuged and the supernatant was
aspirated, transferred to a fresh tube on ice, and quantified by
the Bradford method. Protein samples were prepared from
-80°C frozen sections from 22-week-old human foetal brains
and from glioblastoma lesions. For each kind of tissue,
replicates of sixteen sections, 20 µm-thick, 80 mm2 wide, were
scraped on ice using a wet scraper and immersed in the
extraction buffer (20 mM Tris-HCl pH 8.8, 2% SDS, 200 mM
DTT, 7M Urea, 1 tablet of “complete mini” Roche, 0.8 mM
Pefabloc® SC). Lysates were collected in Eppendorf safe-lock
tubes in a final volume of 800 μl of extraction buffer and
sonicated at the following conditions: 5% output, 5 sec pulse
and 30 sec break cooling on ice, repeating 24 times for a total
sonication time of 2 min per sample. The material was then
heated up to 100°C for 20 min and the extracts clarified for 15
min at 16,000xg at 4°C and quantified by the Bradford method.
Samples were solubilized in 5x SDS-PAGE loading buffer (250
mM Tris-HCl pH 6.8, 2.5% SDS, 35% Glycerol, 0.025% (w/v)
Bromophenol blue, 125 mM DTT) and resolved on Tris-HCl 5%
or pre-cast 4-15% linear gradient gels (Bio-Rad, Richmond,
CA), or native PAGE gels (Life Technologies, Inc.). Precision
Plus Protein™ Dual Xtra standards (2–250 kDa) and Unstained
HiMark Standards (Life Technology Inc.) were employed as
molecular markers. Resolved proteins were transferred
overnight onto nitrocellulose membranes and the membrane
were saturated with 5% dry milk in TBS containing 0.1%
Tween-20. Blocked membranes were incubated with the anti-
NG2/CSPG4 mAbs (1:2 – 1:10 dilution for supernatants, or
1:150 dilution for ascites fluids) in blocking buffer. Membranes
were extensively washed and incubated for 1 hr at room
temperature with rabbit anti-mouse antibodies conjugated to
HRP (Sigma-Aldrich). Immunolabelled bands were visualized
with the ECL Plus Chemiluminescence detection kit (GE
Healthcare, Little Chalfont, UK). A polyclonal antiserum against
β-actin was employed as a calibrator (diluted 1:400 in TBS-
Tween 0,1%), following revealing with the secondary goat anti-
rabbit antibodies conjugated to HRP (Sigma-Aldrich).
Results
Production of mAbs recognizing distinct isoforms of
NG2/CSPG4
To establish the molecular identity and spatial distribution of
vascular and tumour-associated NG2/CSPG4 molecules, as
well as to highlight putative foetal-adult-neoplastic transitions in
the patterns of PG expression, we generated a panel of 63
murine mAbs against the recombinant ectodomain of human
NG2/CSPG4, that were characterized through a repertoire of
immune-assays and by immunohistochemistry on tissue
sections (see below). The hybridoma clones were initially
screened against a defined, selected panel of tumour cell lines
and from this screening we selected 48 clones that exhibited a
sufficiently high reactivity against one or more of the cell lines
(Table 1). The diverse pattern of immunoreactivity observed
through cell-ELISA and complementary flow cytometry (not
shown) further confirmed the ability of the hitherto produced
panel of antibodies to react with distinct forms of the PG.
Most mAbs were found to detect the widely observed NG2/
CSPG4 doublet migrating at Mr 230-260 kDa and previously
proposed to correspond to two of the most frequently occurring
PG variants encompassing the entire ectodomain, but differing
as regards the presence or absence of the N-terminal Ca2+-
binding module (Table 1). These NG2/CSPG4 variants also
Pericyte Subsets Express NG2/CSPG4 Isoforms
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appeared to be weakly glycosylated and virtually completely
non-glycanated. Whether the seemingly GAG-free NG2/
CSPG4 variants recognized by the antibodies corresponded to
subsets of the PG molecules expressed on the surfaces of the
Table 1. Binding characteristics of anti-NG2/CSPG4 monoclonal antibodies1.
mAb ELISA2 Cell-ELISA3 Flow Cytometry Western Blotting4
 NG2rec A3755 SKUT1 143B  NG2rec A3755 SKUT1 143B  NG2rec A3755 SKUT1 143B
B5/M286 n.a. +++ +++ +++ B5/M286 n.a. +++ +++ +++ B5/M286 n.a. +++ +++ +++
7.1 n.a. n.a. n.a. n.a. 7.1 n.a. n.a. n.a. n.a. 7.1 n.a. n.a. n.a. n.a.
2161A4 >3.0 + +++ ++ 2161A4 >3.0 + +++ ++ 2161A4 >3.0 + +++ ++
2161B1 >3.0 ++ ++ ++ 2161B1 >3.0 ++ ++ ++ 2161B1 >3.0 ++ ++ ++
2161C1 1.32 - - - 2161C1 1.32 - - - 2161C1 1.32 - - -
2161D2 1.21 - - - 2161D2 1.21 - - - 2161D2 1.21 - - -
2161D3 2.47 +++ + ++ 2161D3 2.47 +++ + ++ 2161D3 2.47 +++ + ++
2161D4 0.94 ++ - - 2161D4 0.94 ++ - - 2161D4 0.94 ++ - -
2161D7 >3.0 +++ ++ ++ 2161D7 >3.0 +++ ++ ++ 2161D7 >3.0 +++ ++ ++
2161E1 2.50 ++ + + 2161E1 2.50 ++ + + 2161E1 2.50 ++ + +
2161F8 0.80 - - - 2161F8 0.80 - - - 2161F8 0.80 - - -
2161F9 0.94 ++ ++ ++ 2161F9 0.94 ++ ++ ++ 2161F9 0.94 ++ ++ ++
2161G7 >3.0 - - n.d. 2161G7 >3.0 - - n.d. 2161G7 >3.0 - - n.d.
2161G8 >3.0 - - n.d. 2161G8 >3.0 - - n.d. 2161G8 >3.0 - - n.d.
2161G11 1.34 - - n.d. 2161G11 1.34 - - n.d. 2161G11 1.34 - - n.d.
2161H2 >3.0 ++ ++ ++ 2161H2 >3.0 ++ ++ ++ 2161H2 >3.0 ++ ++ ++
2161H3 >3.0 +++ +++ ++ 2161H3 >3.0 +++ +++ ++ 2161H3 >3.0 +++ +++ ++
2161H8 >3.0 ++ ++ ++ 2161H8 >3.0 ++ ++ ++ 2161H8 >3.0 ++ ++ ++
2163A1 >3.0 ++ - - 2163A1 >3.0 ++ - - 2163A1 >3.0 ++ - -
2163C3 >3.0 +++ ++ + 2163C3 >3.0 +++ ++ + 2163C3 >3.0 +++ ++ +
2163D7 1.27 ++ ++ ++ 2163D7 1.27 ++ ++ ++ 2163D7 1.27 ++ ++ ++
2163F4 >3.0 ++ ++ - 2163F4 >3.0 ++ ++ - 2163F4 >3.0 ++ ++ -
2163H4 >3.0 +++ ++ ++ 2163H4 >3.0 +++ ++ ++ 2163H4 >3.0 +++ ++ ++
2164A2 1.68 +++ ++ ++ 2164A2 1.68 +++ ++ ++ 2164A2 1.68 +++ ++ ++
2164A7 >3.0 ++ + ++ 2164A7 >3.0 ++ + ++ 2164A7 >3.0 ++ + ++
2164B6 >3.0 +++ ++ - 2164B6 >3.0 +++ ++ - 2164B6 >3.0 +++ ++ -
2164C3 >3.0 ++ + - 2164C3 >3.0 ++ + - 2164C3 >3.0 ++ + -
2164G7 >3.0 ++ ++ ++ 2164G7 >3.0 ++ ++ ++ 2164G7 >3.0 ++ ++ ++
2164H5 1.99 - +++ + 2164H5 1.99 - +++ + 2164H5 1.99 - +++ +
2164H9 >3.0 - + - 2164H9 >3.0 - + - 2164H9 >3.0 - + -
2166G4 >3.0 ++ ++ +++ 2166G4 >3.0 ++ ++ +++ 2166G4 >3.0 ++ ++ +++
2166G2 0.53 n.d. - - 2166G2 0.53 n.d. - - 2166G2 0.53 n.d. - -
2172A2 2.01 - + ++ 2172A2 2.01 - + ++ 2172A2 2.01 - + ++
2172B5 2.28 +++ + ++ 2172B5 2.28 +++ + ++ 2172B5 2.28 +++ + ++
2172B12 >3.0 - + - 2172B12 >3.0 - + - 2172B12 >3.0 - + -
2172C2 >3.0 - ++ ++ 2172C2 >3.0 - ++ ++ 2172C2 >3.0 - ++ ++
2172C3 1.9 - - - 2172C3 1.9 - - - 2172C3 1.9 - - -
2172C10 2.05 - - ++ 2172C10 2.05 - - ++ 2172C10 2.05 - - ++
2172C12 >3.0 ++ ++ +++ 2172C12 >3.0 ++ ++ +++ 2172C12 >3.0 ++ ++ +++
2172D6 >3.0 ++ + + 2172D6 >3.0 ++ + + 2172D6 >3.0 ++ + +
2172D12 2.82 - - + 2172D12 2.82 - - + 2172D12 2.82 - - +
2172E8 >3.0 ++ - + 2172E8 >3.0 ++ - + 2172E8 >3.0 ++ - +
2172E9 >3.0 ++ - + 2172E9 >3.0 ++ - + 2172E9 >3.0 ++ - +
2172F4 2.35 ++ - + 2172F4 2.35 ++ - + 2172F4 2.35 ++ - +
2172F11 1.18 - - - 2172F11 1.18 - - - 2172F11 1.18 - - -
2172G3 1.66 - - - 2172G3 1.66 - - - 2172G3 1.66 - - -
2172G4 1.39 - - - 2172G4 1.39 - - - 2172G4 1.39 - - -
2172G6 1.26 - - - 2172G6 1.26 - - - 2172G6 1.26 - - -
2172H6 2.83 - + - 2172H6 2.83 - + - 2172H6 2.83 - + -
2172H12 2.50 ++ - +++ 2172H12 2.50 ++ - +++ 2172H12 2.50 ++ - +++
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examined cell lines, or whether they corresponded to the
representative NG2/CSPG4 molecules of these cells, remains
to be established. Antibodies 2161F9 and 2161D7 additionally
detected a series of proteolytic fragments of NG2/CSPG4
presumed to have been generated by endogenous proteases
of HEK293 cells in which the ectodomain fragment was
expressed as a recombinant protein. Typical endogenous
proteolytic fragments had an apparent Mr of 100-150 kDa
(Table 1). Antibody 2161D3 preferentially reacted with a
somewhat smaller variant of NG2/CSPG4 running at 220-230
kDa, as well as a substantially more glycosylated isoform in
A375 melanoma cells (Table 1).
Identification of distinct isoforms of NG2/CSPG4 on
glioblastoma and foetal brain sections
In the foetal human cortex, lodging active angiogenic
processes, sprouting vessels and newly formed, still poorly
stabilized vascular structures are rich in NG2/CSPG4-
expressing pericytes, which we have previously shown to be
primary actors in the formation of these nascent vessels [34].
By contrast, NG2/CSPG4 expression is downregulated in
pericytes associated with quiescent vessels [14], and in adult
human brain we found that NG2/CSPG4 is virtually absent in
pericytes of stable microvessels [34] (see also Figure S1A-F).
This would indicate that glioblastoma neovessels, known to be
composed of NG2/CSPG4-expressing pericyte subsets, are
more similar to the developing than to the adult vasculature.
Starting from these basic observations, comparative
immunolabellings were performed on paraffin sections of both
human foetal brain and glioblastoma with the 48 clones
resulting from the immune-assays screening. These 'in situ'
experiments identified a total of 14 clones, of the 48 tested, that
detected differently distributed cell variants of the NG2/CSPG4
PG as well as the presence of cell surface-shed NG2/CSPG4
fragments that remained entrapped in the ECM (Table 2). Four
classes of mAbs were identified according to the qualitative
and quantitative differences observed in revealing the
corresponding NG2/CSPG4 isoforms (Table 2). For each class,
a prototype clone (i.e. mAbs 2164H5, 2161F9, 2161D7, and
2166G4; Table 2 and Figure S2), characterized by its
distinctive and intense IHC signal, was designed to represent
its distributional class in the subsequent confocal microscopy
analysis.
Immunohistochemical characterization of glioblastoma
neovessels
Heterogeneity in tumour microvascular architecture includes
a variable expression of EC (endothelial cell) and pericyte
markers and reflects the origin, density, structure, and tissue
distribution of the newly formed vessels. For this reason, we
firstly applied a panel of vessel markers that could define in
more detail (i) the structural and compositional properties of
intra-lesional vessels of glioblastoma, (ii) the tumoral areas
characterized by a precise vessel typology denoted
'glomeruloid bodies' and 'garland vessels', both described as
forms of endothelial and pericyte proliferation [10,35,36], and
(iii) the spatial organization of ECs and pericytes also in
relation to their surrounding vascular basement membrane
(VBM). Preliminary, peripheral tumour areas, as well as areas
Table 2. Anti-human NG2/CSPG4 proteoglycan clones
selected by IHC on paraffin-embedded samples of
glioblastoma and foetal brain and listed according to their
distributional staining pattern1.
mAb Glioblastoma Foetal brain
 ECM PCs  ECM PCs  ECM
2164H52 ++++ +++ 2164H52 ++++ +++ 2164H52 ++++
2172D12 +++ ++ 2172D12 +++ ++ 2172D12 +++
2172F11 +++ ++ 2172F11 +++ ++ 2172F11 +++
2161D4 ++ ++ 2161D4 ++ ++ 2161D4 ++
2161F9 - ++++ 2161F9 - ++++ 2161F9 -
2161D7 - ++++ 2161D7 - ++++ 2161D7 -
2161A4 - - 2161A4 - - 2161A4 -
2164G7 - +++ 2164G7 - +++ 2164G7 -
2166G4 - - 2166G4 - - 2166G4 -
2172B12 - - 2172B12 - - 2172B12 -
2172C3 - - 2172C3 - - 2172C3 -
2172C12 - - 2172C12 - - 2172C12 -
2172D6 - - 2172D6 - - 2172D6 -
2172H6 - - 2172H6 - - 2172H6 -
1 Detailed analyses of the IHC properties of the antibodies were performed on a
selection of 48 of the 63 hybridoma clones originally produced.2 In 'bold' the
prototype hybridoma clone for each identified isoform class.. Semi-quantitative
scoring of IHC reactivity: “-“, very weak or absent; “+”, weak; “++”, intermediate ; “+
++”, strong; “++++”, very strong. Abbreviations: ECM, extracellular matrix; PCs,
pericytes; PPCs, pericyte precursor cells; TCs, tumoral cells; OPCs,
oligodendrocyte precursor cells.
doi: 10.1371/journal.pone.0084883.t002
Table 1 (continued).
1 Detailed analyses of the binding properties of the antibodies were performed on a selection of 49 of the 63 hybridoma clones originally produced. 2 Performed as a solid-
phase binding assays with HRP-based colorimetric detection on the recombinant NG2/CSPG4 extracellular fragment used as immunogen. 3 Performed as a solid-phase
binding assay with HRP-based colorimetric detection on PFA fixed cells. 4 Performed on material resolved by SDS-PAGE (4-15% gradient gels) under reducing conditions. 5
Human cell lines were as follows: A375, M2 and COLO-38, melanoma; SK-UT-1 and SK-LMS-1, leiomyosarcoma; HT1080, fibrosarcoma; 143B, osteosarcoma. 6 MAbs
B5/M28 and PE-conjugated 7.1 were used as reference antibodies for Western blotting and flow cytometry, respectively. Semi-quantitative positivity scoring for cell-ELISA
and flow cytometry was as follows: “-”, 0-15%; “+”, 15-25%; “++”, 25-50%; “+++”, 50-75%; “++++”, 75-100%. Abbreviations: n.a., not applicable; n.d., not determined.
doi: 10.1371/journal.pone.0084883.t001
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where necrotic, pseudopalisading and/or haemorrhagic aspects
prevailed, were not included in the study (Figure S3).
Reference EC markers were the ubiquitous junction-associated
Ig-like protein PECAM-1/CD31, the enzyme MMP2, the
transmembrane receptor endoglin/CD105, and the integral
membrane glycoprotein Mel-CAM/CD146, all of which are
highly expressed in angiogenically active ECs and in metastatic
processes [37-41] (Figure 1A-D, H, I). Mature and activated
pericytes were immunolocalized by αSMA, PDGFRβ,
endosialin/CD248 [34,42], and NG2/CSPG4 D2 (Figure 1E-I;
Figure S4A-F). VBM was delineated by collagen type IV (Coll
IV) (Figure 1B-D). The typical multilaminar arrangement of the
tumour VBM, that is a hallmark of the "garland vessels"
phenotype [10,35,36,43], was revealed on sections
immunolabelled with anti-Coll IV and with NG2/CSPG4 D2
antiserum, which also recognized fragmented PG, possibly
released by cell surface proteolysis (Figure 1D, E, H, I; Figure
S4A, C, D, F). EC markers showed monolayers of activated
MMP2/CD105-reactive ECs (Figure 1A, D, I), while CAM/
CD146 characteristically decorated the luminal EC membrane
(Figure 1C) and CD31 revealed microvesicles-like structures
showing a diameter ranging from 1.57 to 3.44 µm, which
appeared to be detached from the luminal EC membrane
(Figure 1B and Movie S1). Pericytes were revealed to be
organized in multistrata and the detailed immunolocalization of
NG2/CSPG4 D2 together with αSMA, PDGFRβ, and CD248
discriminated between two spatially separated populations: one
directly facing the EC lining (αSMA-, phospho-PDGFRβ,
CD248-expressing pericytes) and one, more externally located,
formed by NG2/CSPG4 D2-reactive pericytes (Figure 1E-G;
Figure S4A-F; Movie S2). Unlike NG2/CSPG4, that was equally
distributed in pericytes, the phosphorylated form of PDGFRβ
showed a distinct subcellular polarization with a preferential
accumulation at the endothelial-pericyte interface (Figure 1F
and Figure S4A-C).
Differential expression of NG2/CSPG4 isoforms in
glioblastoma lesions and foetal brain unveils pericyte
subsets
In the glioblastoma neovessels, mAb 2164H5 identified a
pericyte subset that was juxtaposed to the Coll IV-containing
VBM, but also recognized surface-released fragments of the
PG that crusted the outer vessel surface and could be
discerned occupying intercellular spaces of the lesion (Figures
2A, B). This suggested that the epitope recognized by mAb
2164H5 in NG2/CSPG4 was retained in the proteolytic
fragments of its ectodomain. An analogous distribution pattern
of this NG2/CSPG4 isoform was observed in the subventricular
zone of foetal brain, where cell surface-shed fragments of the
PG were observed in the ECM and around the vessel wall
(Figure 2C, D). Interestingly, in the telencephalic ECM,
released 2164H5-reactive NG2/CSPG4 fragments seemed to
be excluded from the ventricular zone and to be progressively
increased through the subventricular zone to the cortical plate
(Figure 2C).
Double immunolabellings performed with mAb 2161F9 and
antibodies to Coll IV and Coll VI (Figure 3A, B) or the pAb NG2/
CSPG4 D2 (Figure 3C-F) revealed that in glioblastoma tissues
these specific isoforms accumulated at the endothelium/
pericyte interface and thereby, as compared with NG2/CSPG4
D2, immunolocalized the innermost pericyte subset (Figure
3C). At this location, the NG2/CSPG4-expressing pericyte
subset contacted the Coll IV stratified VBM, whereas Coll VI
was organized in a monolayer associated with the pericyte
basal side. These pericyte subpopulations showed a different
frequency and spatial arrangement in neovascular beds of
glioblastoma and the microvessels of foetal brain (Figures 3G-
I). Whereas the pericyte population marked by expression of
2161F9-reactive isoforms structured the entire luminal surfaces
of glioblastoma vessel walls, in partial continuity with the Coll
IV-containing stratified VBM and in a contiguous manner with
the surrounding Coll VI (Figures 3A, B), the pericyte phenotype
revealed by this isoform in foetal brain corresponds to single,
often isolated pericytes, which were clearly seen to embrace
the microvessel wall with short processes and partially cover
the Coll IV/Coll VI/NG2/CSPG4 D2-containing VBM (Figures
3G-I). Clone 2161F9 in double immunolabelling with NG2/
CSPG4 D2 pAb disclosed, together with the described subset
of pericytes, a number of intraluminal cells having an average
size of ~9µm (8.99µm ± 0.43µm) (Figure 3D-F and Figure S5A-
C, A'-C'). Since these cells were found to be negative for CD3,
CD31, CD45, CD146 and CD105, they were initially defined as
NG2-reactive precursor-like cells and subsequently definitely
identified, thanks to double labelling with mAb 2161F9 and the
pericyte marker PDGFRβ as pericyte progenitor cells (PPCs)
(Figure S5D-F) [44].
Evidence of clone selectivity in recognizing different NG2/
CSPG4 isoforms was obtained by double immunolabelling with
2164H5 and 2161F9. On these sections, although a close
vicinity was noted between the isoforms, the respective signals
did not coincide and partially overlapped only on the vessel
wall: mAb 2161F9 was restricted to the pericyte subset,
whereas mAb 2164H5 reactivity appeared to be more directly
related to the VBM and to shed fragments of the PG present in
the tumour intercellular spaces (Figure 4A-F). Interestingly, in
areas of the lesion where aspects of vascular and tumoral cell
proliferation abounded, dividing pericytes still distinctly labelled
by clone 2161F9 were seen, together with proliferating tumour
cells that, during mitosis, accumulate 2164H5-reactive NG2/
CSPG4 within the cytoplasm and close to the dividing
chromosome (Figure 4D-F).
On glioblastoma tissue, prototype mAb 2161D7, and clone
2164G7 belonging to the same class (Table 2), again revealed
pericyte-specific NG2/CSPG4 isoforms. However, the
molecular species identified by these mAbs appeared more
ubiquitous among the tumour vessels and through the pericyte
strata. In fact, on double immunolabellings with Coll IV and VI,
sites of colocalization coincided with the outer aspect of the
Coll IV VBM rather than with Coll VI (Figure 5A-C), while in the
innermost pericyte stratum 'niches' of proliferation were also
seen, formed by 2164G7- and 2164G7/Coll VI-reactive
pericytes (Figure S6A-C). In foetal brain, NG2/CSPG4 isoforms
revealed by mAb 2161D7 appeared extensively distributed on
the pericyte layer and also disclosed ramified cells. These
NG2/CSPG4-reactive cells, never seen with other anti-NG2/
CSPG4 clones, appeared sparse in the subventricular zone
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Figure 1.  Spatial organization of ECs and pericytes within the glioblastoma neovessel wall in relation to the multilaminar
VBM.  (A) Colocalization of MMP2 and CD105 on tumoral ECs; (B-D) relative localization of CD31-, CD146-, and MMP2-reactive
ECs in tumour vessels characterized by a thick, multilaminar Coll IV VBM. (E-G) The multilayered arrangement of NG2/CSPG4 D2-
expressing pericytes and the relative innermost localization of αSMA (E), PDGFRβ (F), and endosialin/CD248 (G) immunolabelled
pericytes. (H, I) Perivascular distribution of cell surface-shed fragments of the PG NG2; note in (C) restricted Mel-CAM/CD146
reactivity on the luminal EC plasma membranes, in (E, inset) the alternate αSMA cytoplasmic reactivity and cell and membrane-
associated NG2 D2 labelling, and in (F) the activated form of PDGFRβ revealed on the adluminal pericyte plasma membrane.
Nuclear counterstaining TO-PRO3. Bars 20 µm.
doi: 10.1371/journal.pone.0084883.g001
Pericyte Subsets Express NG2/CSPG4 Isoforms
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e84883
Figure 2.  Distribution of NG2/CSPG4 isoforms recognized by mAb 2164H5 in glioblastoma and foetal brain.  (A) 2164H5/
Coll IV double immunolabelling shows 2164H5-reactive NG2/CSPG4 isoforms close to pericytes fully embedded in the VBM;
proteolytic fragments of these isoforms appear dispersed through the stromal ECM (asterisk) and decorate glioblastoma cells. (B)
High magnification view of the neovessel marked with a star in (A) in which this specific pericyte subset preferentially localizes in a
more abluminal position with respect to the Coll IV-containing VBM, and resides in mural 'pericyte lacunae' (arrows). (C, D) The
distribution of NG2/CSPG4 isoforms recognized by mAb 2164H5 in foetal brain closely resembles that seen in glioblastoma
neovessels; notably (C), NG2/CSPG4 fragments form a concentration gradient which increases from the ventricular zone (VZ)
through the subventricular zone (SVZ) and close to the vessel wall (D, arrowheads). Nuclear counterstaining TO-PRO3. Bars A, C
25 µm; B, D 10 µm.
doi: 10.1371/journal.pone.0084883.g002
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Figure 3.  Expression of 2161F9-reactive NG2/CSPG4 isoforms by pericyte subsets.  (A-C) Double immunolabellings of
glioblastoma lesions with mAb 2161F9 and antibodies to Coll IV, Coll VI, or the NG2 D2 pAb, specifically show that the pericyte
subpopulation expressing these isoforms is organized in the innermost pericyte layers of both 'garland' vessels (A) and smaller
neovessels characterized by the typical proliferative appearance of EC whose nuclei bulge into the vessel lumen (B, C; arrows). (D-
F) Capturing of pericyte precursor-like cells 2161F9-reactive NG2/CSPG4 isoforms within the vessel lumen and adherent to the
vessel wall (arrows in E and F, enlargements of D). (G-I) A pericyte subset expressing the NG2/CSPG4 isoform recognized by mAb
2161F9 is also seen in foetal brain, where its specificity is confirmed, allowing a clear-cut view of the pericyte cell body and
processes (high magnification of G in G'). Nuclear counterstaining TO-PRO3. Bars A-C 10 µm; D 20 µm; E-G, H, I 10 µm; G' 5 µm.
doi: 10.1371/journal.pone.0084883.g003
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and more numerous in the intermediate zone (the emerging
white matter in 22-week-old foetal telencephalon) (Figure 5D-F
and Figure S7A-C), featuring a temporal and spatial distribution
consistent with an OPCs (oligodendrocyte precursor cells)
phenotype [45]. Some of them were identified by the O4-
antigen, which recognizes specific glycolipids and cholesterol
in OPCs in the course of their differentiation to pre-
oligodendrocytes [46,47] (Figure S7D-F).
The most unique NG2/CSPG4 isoform was found to be the
one recognized by mAb 2166G4. This was noted to be
exclusive of glioblastoma (Figure 6A-E), being entirely absent
in foetal brain. In tumour tissues, mAb 2166G4 revealed
tumour cells scattered in the stroma and forming typical
perivascular cuffing, a distributional pattern that was never
seen with the described pericyte-specific isoforms (i.e. with
mAbs 2161F9 and 2161D7). The observation of a restricted
expression of the isoform revealed by clone 2166G4 on
neoplastic cells and its specificity as compared to the pericytes-
specific ones, was verified by comparing 2166G4/Glut-1 and
2161D7/Glut-1 double immunolabellings (Figure 6D-F and G-I,
respectively). Interestingly, Glut-1 was largely co-localized with
the NG2/CSPG4 isoform detected by mAb 2166G4 on
neoplastic cells scattered in the tissue and in the vicinity of
tumour vessels (Figure 6D-F). On the contrary, Glut-1 was
never seen to colocalize with the pericyte-specific isoform of
the PG revealed by clone 2161D7, being detectable only on
tumoral cells (Figure 6G-I).
Figure 4.  Comparative distribution patterns of two different NG2/CSPG4 isoforms revealed in glioblastoma lesions by
double labelling with mAbs 2164H5 and 2161F9.  (A-C) mAb 2164H5 (A) primarily discloses cell surface-released fragments of
NG2/CSPG4 included in the VBM (arrowheads) and present in the intercellular spaces (asterisk), whereas mAb 2161F9 (B) defines
the pericyte layer (arrows); on the merged image (C), the diverse NG2/CSPG4 expression profiles are clearly recognizable. (D) In a
tumour area rich in ECM, clone 2161F9 reveals actively dividing pericytes (arrows), shown in detail in (E) (arrow a, prophase and
arrow b, telophase), and two tumour cells, enlarged in (F), in advanced anaphase of mitosis (arrowheads); note in (F) NG2/CSPG4
aggregates next to the dividing chromosomes (arrowheads). Nuclear counterstaining TO-PRO3. Bars A-C, 20 µm; D, 25 µm; E, F
10 µm.
doi: 10.1371/journal.pone.0084883.g004
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Immunochemical traits of NG2/CSPG4 isoforms
expressed in foetal brain and glioblastoma
Of the 30 mAbs recognizing the recombinant NG2 antigen in
immunoblotting (NG2rec; Table 1), 8 reacted with NG2/CSPG4
isoforms expressed by foetal brain tissues or glioblastoma
lesions, or both, yielding distinctive banding patterns (Figure 7).
In general, a more diversified banding pattern was observed
with the recombinant NG2/CSPG4, suggesting that once
expressed as an ectodomain fragment in HEK293 the PG was
particularly susceptible to degradation by proteases produced
by these cells. Primary proteolytic fragments of both foetal
brain and glioblastoma ranged from 140-250 kDa. The
melanoma cell line M2, although expressing high levels of
NG2/CSPG4 in up to 90% of the cells (as determined by flow
cytometry), failed to be recognized by any of the mAbs (Figure
7). The most striking difference was noted when comparing the
isoforms recognized by the different antibodies in foetal brain,
A375 cells and glioblastoma. Differences were particularly
accentuated when considering the apparently diverse
glycosylation patterns of the recognized NG2/CSPG4 isoforms
of pericytes/OPCs versus tumour cells, i.e. as in the case of
mAbs 2166G4 and 2172D6 versus mAb 2161F9 (Figure 7).
Another interesting finding was that the isoforms recognized by
the majority of mAbs in A375 melanoma cells were consistently
less glycosylated than those expressed by pericytes/OPCs and
possibly glioblastoma cells. This observation precludes the
possibility that the mAbs reacted with discrete glycosylation
isoforms, which in that case should have been the same for
each tissue specimen. Sharper bands observed with several of
the antibodies suggested that they recognized the NG2/CSPG4
core protein also in its partially unfolded form (i.e., during
intracellular processing).
Figure 5.  Expression of NG2/CSPG4 isoforms recognized by mAb 2161D7 in glioblastoma and foetal brain.  (A) NG2/
CSPG4 isoforms detected by mAb 2161D7 appear ubiquitously distributed through the pericyte layers, decorating the luminal side
of glioblastoma neovessels and co-localizing with the outermost VBM Coll IV layers. (B) 2161D7-reactive multilayered pericytes
surrounded by Coll VI VBM. (C) A 'naked' tumour vessel with a thin layer of pericytes without a detectable Coll VI VBM. (D-F)
Identical double stainings of foetal brain to those performed on glioblastoma sections confirm an analogous spatial arrangement of
the pericyte population marked by mAb 2161D7-reactive NG2/CSPG4 isoforms, and additionally highlight the expression of such
isoforms on typical foetal OPCs (arrowheads). Nuclear counterstaining TO-PRO3. Bars A, C, F 20 µm; B, D, E 25 µm.
doi: 10.1371/journal.pone.0084883.g005
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Figure 6.  Expression of NG2/CSPG4 isoforms recognized by mAb 2166G4 in glioblastoma cells.  (A-C) Immunolabelling with
mAb 2166G4 shows the specific expression of these NG2/CSPG4 isoforms by the tumour cells, frequently seen forming
perivascular cuffs (V in A and B). (D-F) Coincident staining of tumour cell 2166G4-reactive isoforms and Glut-1. (G-I) mAb 2161D7,
identifying pericyte-specific NG2/CSPG4 isoforms, does not stain Glut-1-reactive tumoral cells that in this case do not infiltrate the
vessel wall (V), providing indirect evidence of NG2/CSPG4 isoform specificity. Nuclear counterstaining TO-PRO3. Bars A 50 µm; B-I
10 µm.
doi: 10.1371/journal.pone.0084883.g006
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Figure 7.  Immunochemical characteristics of NG2/CSPG4 isoforms and their proteolytic fragments in foetal brain,
glioblastoma and neoplastic cells.  Sections from foetal brain and glioblastoma samples were taken adjacently to sections in
which abundant neovessels and enrichment of NG2/CSPG4-expressing pericytes were revealed by immunostaining. The sections
were then processed for immunoblotting with the anti-NG2/CSPG4 mAbs (see M & M). A375 and M2 melanoma cells, and the
recombinant NG2 ectodomain (NG2rec), used for producing the mAbs, were blotted in parallel for reference. Since mAb 2164H5 did
not react with the cognate isoform in Western blotting, it was used to immunoprecipitate the isoform, which was then blotted with
mAb B5/M28. The co-recognized isoform is likely to be only one of the NG2/CSPG4 variants and their cell surface-shed fragments
immunoprecipitated by mAb 2164H5. Immunoblotting of α-actin with a polyclonal antiserum was used for normalization of gel lane
loading. The relative position of molecular weight markers is indicated to the left of each panel.
doi: 10.1371/journal.pone.0084883.g007
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Discussion
To provide insights into the cellular and molecular
architecture of the angiogenic microvasculature of glioblastoma
lesions, and compare their arrangement with those of healthy
foetal and adult vasculature of the human brain, we generated
a large panel of mAbs against the extracellular portion of
human NG2/CSPG4 – a widely recognized critical surface
component of active pericytes. We then made use of these
antibodies to perform high-resolution fluorescence microscopy
in conjunction with immune-mapping based upon endothelial
markers and antibodies directed against perivascular ECM
components. This approach allowed us to corroborate the
expression of NG2/CSPG4 in subpopulations of glioblastoma
cells [15-17] and disclose, for the first time, precisely organized
pericyte subsets associated with nascent vessels of both foetal
brain and glioblastoma. Furthermore, we were able to unveil
NG2/CSPG4 isoforms that were pericytes-elective, i.e. not
expressed by glioblastoma cells, or their associated non-
neoplastic cells, and isoforms that appeared to be specific to
the cancer cells as they were neither present on tumour
vessels nor in foetal vessel pericytes.
A first characterization of the specificity of the anti-NG2/
CSPG4 mAbs was based upon binding studies with tumour cell
lines and indicated that the antibodies recognized NG2/CSPG4
variants that may in part be generated through differential post-
translational modifications. Conversely, differential binding
properties of the antibodies did not seem to be connected with
diverse glycanation profiles of the PG. A more thorough
characterization of the structural-compositional traits of these
NG2/CSPG4 variants is therefore currently being pursued
through extended protein sequence analyses. Some of the
antibodies also reacted effectively with epitopes retained within
fragments of the NG2/CSPG4 ectodomain, which were
presumably released by cell surface proteolysis under both
physiological and pathological conditions. Direct comparisons
with the reactivity traits of antibodies reported in the literature
further highlight their unique specificity for discrete variants of
the PG. The possibility that the mAbs cross-reacted with other
antigens could largely be excluded on the basis of a number of
facts and empirical observations. Firstly, the uniqueness of the
primary structure of NG2/CSPG4 within the human genome
argues against the presence of immunodominant amino acid
sequence stretches shared by other human proteins. Secondly,
immunochemical reactivities were consistently abrogated by
preincubation of the antibodies with the recombinant NG2/
CSPG4 ectodomain used as immunogen. Thirdly, no reaction
was seen with the antibodies when these were screened
against cell lines not expressing NG2/CSPG4. Finally, mass
spectrometric analyses, performed within the framework of a
different ongoing study on NG2/CSPG4 molecules
immunoprecipitated from different tumour cell lines, do not
disclose peptide sequences belonging to other proteins.
As a first step toward the mapping of pericytes in
glioblastoma vessels, we carried out a detailed analysis of the
cellular arrangement characterizing the aberrant vascular
structures known to be elaborated inside glioblastoma lesions,
i.e. dilated, multilaminar “garland vessels" [10,36], and
compared these structures to the angiogenic vessels of the
developing human brain. Subsequent analyses based on the
prototype mAbs 2161F9 and 2161D7 and other clones
belonging to the same groups showed that both the developing
brain and glioblastoma lesions embodied vessels made up of
pericytes expressing more than one molecular form of NG2/
CSPG4, and thereby discerned as discrete subsets.
In glioblastoma vessels, NG2/CSPG4-expressing pericytes
were found to be associated with the VBM and to contribute to
the 'garland' appearance of the vessels, identifying at least two
phenotypically distinct and spatially separated pericyte
populations. The internal one seemed to correspond to a
population actively engaged in the construction of the vessel
and possible extensions; to this subset also belonged the
luminally arranged, dividing pericytes revealed. The other,
more external population was often surrounded by an
unusually stratified VBM that, at least in part, may have been
deposited by the pericytes themselves. VBM multiple layers
have been demonstrated by electron microscopy in tumour
models of mouse carcinomas, where they are associated with
structural abnormalities and may reflect tumour dynamics of
endothelial cells and pericytes [43]. These two pericyte subsets
were also polarized with respect to the luminal-abluminal axis
of the vessel and accumulated surface molecules known to be
critically involved in their vessel stabilizing function, including
NG2/CSPG4 itself, PDGFRβ and endosialin/CD248. The
precise functional properties of these subsets and how they are
generated and maintained remain, of course, to be established.
These observations provide concrete evidence at the single
cell level of a spatio-functional distribution of tumour pericytes,
which is directed toward the overlaying endothelium and may
be instrumental in the pivotal interactions between the two cell
types.
Apart from the typical pericyte-specific staining described
with mAbs 2161F9 and 2161D7 and their relative clones, these
two mAbs showed a significantly different potential for unveiling
additional cell lineages. (i) In glioblastoma, mAb 2161F9
revealed pericyte precursor cells (PPCs) within the lumen of
the tumour vessel network. These cells, which showed a
progenitor-like small size and morphology with a high nucleus/
cytoplasm ratio, lacked other markers of leukocytes and
endothelial progenitor cells, such as CD3, CD31, CD45, CD146
and CD105, but expressed PDGFRβ that, in our double
staining, was co-localized to a small degree with isoforms of
NG2/CSPG4 revealed by mAb 2161F9, thus confirming that
these NG2/CSPG4-reactive cells show, in part, a pericytic
phenotype [44]. An increased frequency of PPCs was found in
patients and mice with malignant tumours and in type 2
diabetic patients shown to have microangiopathy [23,44,48]. To
the best of our knowledge, PPCs have never been described in
glioblastoma; therefore, although an investigation of the role of
PPCs is well beyond the scope of this work, we must not ignore
the fact that these cells have been suggested to be involved in
neoplastic perivascular cell differentiation, vascular survival,
and cancer-related angiogenesis, aspects of primary
importance in these extremely vascularized tumours [24]. (ii) In
glioblastoma, mAb 2161D7 and other members of the same
group demarcated NG2/CSPG4 isoforms that also reveal
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perivascular proliferating pericytes. Niches of proliferating
pericytes are likely to be connected with tumour
neovascularization phenomena, too. Early participation of
pericytes in neovascularization has been described, shown by
the formation of tubes (vasculogenic mimicry) and initiation of
vascular sprouting [22,34,49,50]. Likewise, human bone
marrow-derived mesenchymal stem cells (hMSCs) and
glioblastoma stem cells (GSCs), pericytes of 'proliferative
niches' might contribute to alternative mechanisms for the
extension of the tumour vascular network by providing a
reservoir of multipotent vascular progenitors [51-53]. (iii) In
addition, in the developing brain, clone 2161D7 disclosed
human OPCs (oligodendrocyte precursor cells), glial progenitor
cells characterized by a NG2/O4-reactive phenotype that
differentiate into myelinating oligodendrocytes and form a
population of proliferative cells capable, in adult brain, of
regenerating myelin following injury and disease [54,55].
Several of our mAbs belonging to the mAb 2164H5 group
also allowed us to immunolocalize cell surface-shed NG2/
CSPG4 fragments 'in situ' in both glioblastoma and foetal brain
VBM and stromal ECM. In tumour vessels, NG2/CSPG4
fragments co-localized with Coll IV at the VBM/pericyte
interface, forming clearcut rims denoted as 'pericyte lacunae',
restricted specific domains pertaining to shed fragments and
never seen to be co-localized with pericyte-specific isoforms
identified by mAb 2161F9. Moreover, testifying to the origin of
NG2/CSPG4 fragments not only from pericytes within the VBM
but also from glioblastoma cells in the tumour ECM, mAb
2164H5 staining was present in proliferating tumour cells, that
seemed to symmetrically segregate 2164H5-reactive NG2/
CSPG4 isoforms into daughter cell cytoplasmic compartments
[30]. Considering the involvement of the Golgi apparatus in
post-translational glycoprocessing and its dynamic during
mitosis, these may consist of Golgi vesicular and tubular
membranes that are also segregated between the two
daughter cells and, in telophase, fuse to reform the Golgi
complex [56,57]. The idea is that tumour cells may produce an
NG2/CSPG4 form as a secretory molecule, which is detectable
during the phase of mitosis segregation to be thereafter
released into the tumour ECM. Further studies are needed to
support and elucidate the possible meaning of the observed
data.
In contrast to the above ECM and pericyte-specific
antibodies, mAb 2166G4 identified NG2/CSPG4 isoforms that
were electively expressed by glioblastoma cells dispersed
within the lesion and in vascular cuffs. Tumour cells were
identified by co-expression of the glucose transporter isoform 1
(Glut-1). In normal conditions Glut-1 is a specific marker of
blood-brain barrier (BBB)-ECs and has been considered to be
an excellent indicator of a normally functioning barrier, changes
in its expression being related to alterations in tight junctions
and in turn in endothelial barrier/fence activities [58,59]. Glut-1
also appears to be the predominant glucose transporter in
many types of cancer cells, where its overexpression is
associated with an increased tumour invasiveness and poor
clinical prognosis [60-62]. In glioblastoma, the reduction in
Glut-1 expression parallels BBB-EC tight junction alterations
and is consistent with BBB opening in tumour vessels [59,63].
By using Glut-1 as a counter-marker of neoplastic cells it was
possible to visualize glioblastoma cells intermingled with
pericytes around tumour vessels. The selectivity of the mAb
2166G4-reactive NG2/CSPG4 isoforms for neoplastic cells was
also confirmed by the lack of expression of this isoform in both
foetal and adult brain.
Comparative immunoblotting of tissue extracts derived from
regions of the human foetal brain rich in NG2/CSPG4-
expressing neovascular pericytes substantiated the presence
of diverse isoforms of the PG on these cells and highlighted a
widespread proteolytic fragmentation of the extracellular
domain, which seemed different in human foetal brain as
compared to glioblastoma lesions and cultured melanoma cell
lines. This finding may be unexpected considering that,
although tumours produce excessive amounts of
metalloproteinase and other proteases capable of degrading
NG2/CSPG4, such enzymes also accumulate in sprouting
vessels [34]. The key difference explaining the discrepancy
may be that a release of ECM-degrading enzymes during
normal vessel sprouting is a temporally and locally controlled
phenomenon, in direct contrast with the continuous ECM
breakdown that ensues during tumour growth and invasion.
Notably, angiogenic NG2/CSPG4 isoforms of foetal brain
appeared overall to be more glycosylated than their cancer-
associated isoform counterparts. The nature of this
glycosylation and its biological significance remain to be
defined. It remains similarly to be determined what may be the
precise molecular identity of the NG2/CSPG4 fragments
generated by sprouting vessels and whether release of these
fragments contributes to the sequestering of extracellular
signalling molecules (primarily growth factors), as previously
shown for cell surface-shed syndecan fragments [64,65].
Overall, our findings provide the first demonstration of NG2/
CSPG4 isoforms capable of recognizing healthy and neoplastic
pericytes, and isoforms of the PG that effectively distinguish
glioblastoma cells from discrete pericyte subsets. Post-
translational modifications of cell membrane-associated
molecules, truncated membrane-bound or soluble fragments
resulting from proteolytic cleavage, as well as the suggested
presence of tumour cell-derived secreted PG NG2/CSPG4
molecules, may all serve different biological activities whose
roles in glioblastoma vascularization and growth have still to be
ascertained. The observations also highlight clearly delineated
arrangements of perivascular cells whose precise functional
implications deserve further attention. A precise identification of
molecules selectively expressed by the tumour vasculature and
associated with vascular sprouting will contribute to a better
understanding of structural-functional characteristics of the
vascular microenvironment in healthy and diseased CNS and
may have a significant impact on the development of combined
anti-neoplastic/anti-angiogenic therapeutic approaches.
Supporting Information
Figure S1.  Absence of NG2/CSPG4-expressing pericytes
in microvessels of adult normal brain. Human
parahippocampal cortex was double-stained with an antibody
to Coll IV and the pAb NG2 D2 recognizing pericyte-specific
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NG2/CSPG4 isoforms and their proteolysis products (A, B), or
mAbs directed against various isoforms of the PG (C-F). The
Coll IV-containing VBMs are characteristically seen
surrounding the entire pericyte body that appears unstained
(arrows). Nuclear counterstaining TO-PRO3. Bars 10 µm.
(TIF)
Figure S2.  Prototype mAbs as emerged from data
summarized in Table 2 and their representative staining
pattern obtained on paraffin embedded glioblastoma
lesions. mAb 2164H5 recognizes fragments of NG2/CSPG4
isoforms released from the cell surface into the vascular
basement membrane (VBM) and extracellular matrix (ECM).
mAbs 2161F9 and 2161D7 identify pericyte isoforms of the
proteoglycan and mAb 2166G4 identify NG2/CSPG4 isoforms
expressed by tumour cells. Semi-quantitative scoring of
immunoreactivity: “–“, very weak or absent; “+”, weak; “++”,
intermediate ; “+++”, strong; “++++”, very strong.
(TIF)
Figure S3.  Representative images of vascular patterning
in different glioblastoma areas. (A) Most glioblastoma
peripheral regions show a rich network of small neoformed
vessels revealed by Coll IV; (B) small vessels characterized by
an NG2 D2-reactive thick wall occupy central areas of the
tumour tissue; (C) a typical 'garland' vessel revealed by NG2
D2, that also comprises capillary tufts (asterisks). Bars 25 µm.
(TIF)
Figure S4.  Subcellular localization of pericyte markers,
PDGFRβ and αSMA, in double stainings with NG2 D2 on
glioblastoma vessels. (A-C) The antibody against the
phosphorylated form of PDGFRβ selectively identifies the
activated receptor on the pericyte adluminal front. (D-F) Clear-
cut images of the differential localization of αSMA and NG2 D2
in pericytes, even better recognizable in the region of the
nucleus (enlarged in the inset), actin appears concentrated in
the sublemmal cell compartment (arrow), whereas NG2 D2 is
distributed on the luminal plasma membrane (arrowhead).
Nuclear counterstaining TO-PRO3. Bars A-C 25 µm; D-F
10µm.
(TIF)
Figure S5.  PPCs revealed by mAb 2161F9 co-express the
pericyte marker PDGFRβ. (A-C) The tumour vessel, double-
labelled by pAb NG2 D2 and mAb 2161F9, shows an
intraluminal pericyte precursor-like 2161F9-stained cell and its
possible passageway across the tumour vessel endothelium
(arrow); in the corresponding enlargement (A'-C'), confocal
laser detection was maximized to reveal the endothelial cell
profile thanks to the autofluorescence of these cells in both the
laser channels. (D-E) By double staining with the pericyte
marker PDGFRβ, the pericyte nature of an NG2 2161F9-
reactive cell is confirmed (arrowhead). Nuclear counterstaining
TO-PRO3. Bars A-C 20 µm; A'-C' 5 µm.
(TIF)
Figure S6.  Proliferating pericytes disclosed in
glioblastoma vessels by expression of specific NG2/
CSPG4 isoforms. (A-C) Double staining with anti-Coll VI and
mAb 2164G7 discloses actively dividing pericytes in different
phases of mitosis; high magnification views in A'-C'; note in C'
the dividing pericyte that also stains for Coll VI. Nuclear
counterstaining TO-PRO3. Bars A-C 10 µm; A'-C' 5 µm.
(TIF)
Figure S7.  Foetal brain OPCs immunolabelled by NG2
2161D7 and O4. (A-C) Single staining with mAb 2161D7
reveals a wave of migrating OPCs (arrows) in the intermediate
zone of the telencephalic wall (A) and the typical ramified
morphology of these precursor cells (B, C). (D-F) By double
staining with the oligodendrocyte marker O4, the OPC nature
of the NG2 2161D7-reactive cells is confirmed; note a
differentiating OPC whose body only expresses the O4 marker
(arrowhead). Nuclear counterstaining TO-PRO3. Bars A 25 µm;
B-F 10 µm.
(TIF)
Movie S1.  Sequence of single optical plane from the z-
stack image shown in Figure 1B; CD31/Collagen IV
immunolabelling. CD31-stained microvesicles appear
released from the cell surface into the vessel lumen.
(AVI)
Movie S2.  Sequence of single optical plane from the z-
stack image shown in Figure 1G; CD248/NG2D2
immunolabelling. CD248- and NG2D2-expressing pericytes
appears as two spatially separated populations within the
tumour vessel wall.
(AVI)
Table S1.  Complete list of primary and secondary
antibodies.
(DOCX)
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